<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03945825</url>
  </required_header>
  <id_info>
    <org_study_id>18-0011</org_study_id>
    <secondary_id>HHSN272201300015I</secondary_id>
    <nct_id>NCT03945825</nct_id>
  </id_info>
  <brief_title>Flublok or Fluzone With Advax-CpG55.2 or AF03</brief_title>
  <official_title>A Phase I Study to Assess the Safety, Reactogenicity and Immunogenicity of Two Quadrivalent Seasonal Influenza Vaccines (Fluzone(R) or Flublok(R)) With or Without One of Two Adjuvants (AF03 or Advax-CpG55.2) in Healthy Adults 18-45 Years of Age</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institute of Allergy and Infectious Diseases (NIAID)</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase I, randomized, double blinded, clinical trial in up to 240 males and&#xD;
      non-pregnant females, 18-45 years of age, inclusive, who are in good health and meet all&#xD;
      eligibility criteria. This clinical trial is designed to assess the safety, reactogenicity&#xD;
      and immunogenicity of either the 2018/2019 seasonal Fluzone or Flublok Quadrivalent Influenza&#xD;
      Vaccine (QIV) manufactured by Sanofi Pasteur (SP) given without adjuvant or with one of two&#xD;
      adjuvant formulations, AF03 or Advax-CpG55.2. Eight Vaccine and Treatment Evaluation Unit&#xD;
      (VTEU) sites will be included in the study. Study duration is approximately 18 months, and&#xD;
      subject participation duration is 12 months. The primary objectives of this study are: 1) to&#xD;
      assess the safety and reactogenicity of 2018/2019 Fluzone and Flublok with and without AF03&#xD;
      or Advax-CpG55.2 adjuvant; 2) to assess the serum hemagglutination inhibition (HAI) antibody&#xD;
      responses against 2018/2019 QIV strains from baseline (Day 1) to approximately Day 29 after&#xD;
      receipt of 2018/2019 Fluzone and Flublok with and without AF03 or Advax-CpG55.2 adjuvant; 3)&#xD;
      to assess the serum neuraminidase inhibition antibody (NAI) responses by enzyme-linked lectin&#xD;
      assay (ELLA) against NA antigens in the 2018/2019 QIV from baseline (Day 1) to approximately&#xD;
      Day 29 after receipt of 2018/2019 Fluzone and Flublok with and without AF03 or Advax-CpG55.2&#xD;
      adjuvant; 4) to assess the influenza neutralizing (Neut) antibody titer responses against&#xD;
      2018/2019 QIV strains from baseline (Day 1) to approximately Day 29 after receipt of&#xD;
      2018/2019 Fluzone and Flublok with and without AF03 or Advax- CpG55.2 adjuvant.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase I, randomized, double blinded, clinical trial in up to 240 males and&#xD;
      non-pregnant females, 18-45 years of age, inclusive, who are in good health and meet all&#xD;
      eligibility criteria. This clinical trial is designed to assess the safety, reactogenicity&#xD;
      and immunogenicity of either the 2018/2019 seasonal Fluzone or Flublok Quadrivalent Influenza&#xD;
      Vaccine (QIV) manufactured by Sanofi Pasteur (SP) given without adjuvant or with one of two&#xD;
      adjuvant formulations, AF03 or Advax-CpG55.2. Subjects will be stratified by prior receipt of&#xD;
      licensed, seasonal influenza vaccine (defined as receipt of at least one of the 2017/2018&#xD;
      and/or 2018/2019 influenza vaccines) and will be randomly assigned to 1 of 6 treatment arms&#xD;
      to receive a single dose of one of the two seasonal 2018/2019 QIV vaccine formulations with&#xD;
      or without one of the two adjuvants (Day 1). On approximately Day 90, each subject will&#xD;
      receive a single dose of the seasonal 2019/2020 QIV. Groups 1, 2 and 3 will receive 2019/2020&#xD;
      Fluzone QIV and Groups 4, 5 and 6 will receive 2019/2020 Flublok QIV. Eight Vaccine and&#xD;
      Treatment Evaluation Unit (VTEU) sites will be included in the study. Study duration is&#xD;
      approximately 18 months, and subject participation duration is 12 months. The primary&#xD;
      objectives of this study are: 1) to assess the safety and reactogenicity of 2018/2019 Fluzone&#xD;
      and Flublok with and without AF03 or Advax-CpG55.2 adjuvant; 2) to assess the serum&#xD;
      hemagglutination inhibition (HAI) antibody responses against 2018/2019 QIV strains from&#xD;
      baseline (Day 1) to approximately Day 29 after receipt of 2018/2019 Fluzone and Flublok with&#xD;
      and without AF03 or Advax-CpG55.2 adjuvant; 3) to assess the serum neuraminidase inhibition&#xD;
      antibody (NAI) responses by enzyme-linked lectin assay (ELLA) against NA antigens in the&#xD;
      2018/2019 QIV from baseline (Day 1) to approximately Day 29 after receipt of 2018/2019&#xD;
      Fluzone and Flublok with and without AF03 or Advax-CpG55.2 adjuvant; 4) to assess the&#xD;
      influenza neutralizing (Neut) antibody titer responses against 2018/2019 QIV strains from&#xD;
      baseline (Day 1) to approximately Day 29 after receipt of 2018/2019 Fluzone and Flublok with&#xD;
      and without AF03 or Advax- CpG55.2 adjuvant. The secondary objectives of this study are: 1)&#xD;
      to assess protocol specified adverse events of special interest (AESI), medically-attended&#xD;
      adverse events (MAAEs), including new-onset chronic medical conditions (NOCMCs) and&#xD;
      potentially immune-mediated medical conditions (PIMMCs) that occur after receipt of study&#xD;
      product; 2) to assess the HAI, Neut and NAI ELLA responses to the 2019/2020 QIV strains prior&#xD;
      to (Day 1) and approximately 28 days after vaccination with the 2019/2020 QIV in all study&#xD;
      groups; 3) to assess the HAI antibody responses against heterologous influenza A/H1 and H3&#xD;
      strains from baseline (Day 1) to approximately Days 8, 29, 57, 90 and 118 after receipt of&#xD;
      2018/2019 Fluzone or Flublok with and without AF03 or Advax-CpG55.2 adjuvant; 4) to assess&#xD;
      NAI ELLA responses against heterologous N1 and N2 NA antigens from baseline (Day 1) to&#xD;
      approximately Days 8, 29, 57, 90 and 118 after administration of 2018/2019 Fluzone with and&#xD;
      without AF03 or Advax-CpG55.2 adjuvant; 5) to assess the influenza neutralizing (Neut)&#xD;
      antibody titer responses against heterologous influenza A/H1 and H3 strains from baseline&#xD;
      (Day 1) to approximately Days 8, 29, 57, 90 and 118 after administration of 2018/2019 Fluzone&#xD;
      and Flublok with and without AF03 or Advax-CpG55.2 adjuvant; 6) to assess the longitudinal&#xD;
      kinetics and durability of the HAI, NAI, and Neut responses against the 2018/2019 QIV strains&#xD;
      on approximately Days 8, 57, 90 and 118 following receipt of the 2018/2019 Fluzone and&#xD;
      Flublok with and without AF03 or Advax-CpG55.2 adjuvant.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 10, 2019</start_date>
  <completion_date type="Actual">September 18, 2020</completion_date>
  <primary_completion_date type="Actual">September 18, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Geometric mean fold rise (GMFR) in hemagglutination inhibition (HAI) titers against the 2018/2019 Quadrivalent Influenza Vaccine (QIV) strains</measure>
    <time_frame>Day 29</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric mean fold rise (GMFR) in neuraminidase inhibition (NAI) titers against neuraminidase (NA) antigens in the 2018/2019 Quadrivalent Influenza Vaccine (QIV) strains</measure>
    <time_frame>Day 29</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric mean fold rise (GMFR) in neutralizing (Neut) titers against the 2018/2019 Quadrivalent Influenza Vaccine (QIV) strains</measure>
    <time_frame>Day 1 through Day 29</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric mean titers (GMTs) of serum hemagglutination inhibition (HAI) against the 2018/2019 Quadrivalent Influenza Vaccine (QIV) strain</measure>
    <time_frame>Day 1 through Day 29</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Occurrence of abnormal clinical safety laboratory adverse events (AEs)</measure>
    <time_frame>Day 1 through Day 8</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Occurrence of all serious adverse events (SAEs)</measure>
    <time_frame>Day 1 through Day 365</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Occurrence of solicited reactogenicity events</measure>
    <time_frame>Day 1 through Day 8</time_frame>
    <description>Both local and systemic AEs will be assessed</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Occurrence of unsolicited adverse events (AEs)</measure>
    <time_frame>Day 1 through Day 29</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of subjects achieving hemagglutination inhibition (HAI) titer seroconversion against 2018/2019 Quadrivalent Influenza Vaccine (QIV) strains</measure>
    <time_frame>Day 29</time_frame>
    <description>HAI seroconversion defined as either a pre-vaccination titer &lt; 1:10 and a post-vaccination titer &gt;/= 1:40 or a pre-vaccination titer &gt;/= 1:10 and a minimum four-fold rise in post-vaccination antibody titer.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of subjects achieving neuraminidase inhibition (NAI) seroconversion</measure>
    <time_frame>Day 29</time_frame>
    <description>NAI seroconversion defined as &gt;/= 4-fold rise in post vaccination antibody titers against the NA antigens in the 2018/2019 QIV.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of subjects achieving neutralizing (Neut) titer seroconversion against the 2018/2019 Quadrivalent Influenza Vaccine (QIV) strains</measure>
    <time_frame>Day 29</time_frame>
    <description>Neut titer seroconversion defined as either a pre-vaccination titer &lt; 1:10 and a post-vaccination titer &gt;/= 1:40 or a pre-vaccination titer &gt;/= 1:10 and a minimum four-fold rise in post-vaccination antibody titer.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of subjects with a neutralizing (Neut) titer &gt;/= 1:40 against the 2018/2019 Quadrivalent Influenza Vaccine (QIV) strains</measure>
    <time_frame>Day 1 through Day 29</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of subjects with hemagglutination inhibition (HAI) titer &gt;/= 1:40 against the 2018/2019 Quadrivalent Influenza Vaccine (QIV) strains</measure>
    <time_frame>Day 1 through Day 29</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Ratio of geometric mean titers (GMTs) of serum hemagglutination inhibition (HAI) against the 2018/2019 Quadrivalent Influenza Vaccine (QIV) strains between adjuvanted and unadjuvanted study groups</measure>
    <time_frame>Day 1 through Day 29</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Ratio of serum neuraminidase inhibition (NAI) geometric mean titer (GMT) between adjuvanted and unadjuvanted study groups</measure>
    <time_frame>Day 1 through Day 29</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Ratio of serum neutralizing (Neut) geometric mean titer (GMT) between adjuvanted and unadjuvanted study groups</measure>
    <time_frame>Day 1 through Day 29</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum neuraminidase inhibition (NAI) geometric mean titer (GMT)</measure>
    <time_frame>Day 1 through Day 29</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum neutralizing (Neut) geometric mean titer (GMT)</measure>
    <time_frame>Day 1 through Day 29</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Geometric mean fold rise (GMFR) in hemagglutination inhibition (HAI) against heterologous H1 and H3 influenza strains</measure>
    <time_frame>Day 1 through Day 118</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric mean fold rise (GMFR) in hemagglutination inhibition (HAI) titers against the 2018/2019 Quadrivalent Influenza Vaccine (QIV) strains</measure>
    <time_frame>Day 1 through Day 118</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric mean fold rise (GMFR) in neuraminidase inhibition (NAI) titers against the 2018/2019 Quadrivalent Influenza Vaccine (QIV) strains</measure>
    <time_frame>Day 1 through Day 118</time_frame>
    <description>NAI titers will only be assessed on study groups 1, 2, and 3.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric mean fold rise (GMFR) in neutralizing (Neut) titers against the 2018/2019 Quadrivalent Influenza Vaccine (QIV) strains</measure>
    <time_frame>Day 1 through Day 118</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric mean fold rise (GMFR) in serum neuraminidase inhibition (NAI) against heterologous N1 and N2 neuraminidase (NA) antigens</measure>
    <time_frame>Day 1 through Day 118</time_frame>
    <description>NAI titers will only be assessed on study groups 1, 2, and 3.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric mean fold rise (GMFR) of neutralizing (Neut) antibody titers against heterologous H1 and H3 influenza strains</measure>
    <time_frame>Day 1 through Day 118</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of protocol specified adverse events of special interests (AESIs)</measure>
    <time_frame>Day 1 through Day 365</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of protocol specified medically-attended adverse events (MAAEs</measure>
    <time_frame>Day 1 through Day 365</time_frame>
    <description>Including new-onset chronic medical conditions (NOCMCs) and potentially immune-mediated medical conditions (PIMMCs)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects achieving a hemagglutination inhibition (HAI) titer &gt;/= 1:40 against 2018/2019 Quadrivalent Influenza Vaccine (QIV) strains</measure>
    <time_frame>Day 8 through Day 118</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects achieving a hemagglutination inhibition (HAI) titer &gt;/= 1:40 against 2019/2020 Quadrivalent Influenza Vaccine (QIV) strains</measure>
    <time_frame>Day 90 through Day 118</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects achieving a hemagglutination inhibition (HAI) titer &gt;/= 1:40 against heterologous H1 and H3 influenza strains</measure>
    <time_frame>Day 1 through Day 118</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects achieving hemagglutination inhibition (HAI) titer seroconversion against 2018/2019 Quadrivalent Influenza Vaccine (QIV) antigens and strains</measure>
    <time_frame>Day 8 through Day 118</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects achieving hemagglutination inhibition (HAI) titer seroconversion against 2019/2020 Quadrivalent Influenza Vaccine (QIV) strains</measure>
    <time_frame>Day 118</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects achieving hemagglutination inhibition (HAI) titer seroconversion against heterologous H1 and H3 influenza strains</measure>
    <time_frame>Day 8 through Day 118</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects achieving neuraminidase inhibition (NAI) titer seroconversion against 2018/2019 Quadrivalent Influenza Vaccine (QIV) antigens and strains</measure>
    <time_frame>Day 8 through Day 118</time_frame>
    <description>NAI titers will only be assessed on study groups 1, 2, and 3.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects achieving neuraminidase inhibition (NAI) titer seroconversion against 2019/2020 Quadrivalent Influenza Vaccine (QIV) strains</measure>
    <time_frame>Day 118</time_frame>
    <description>NAI titers will only be assessed on study groups 1, 2, and 3.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects achieving neutralizing (Neut) titer &gt;/= 1:40 against 2018/2019 Quadrivalent Influenza Vaccine (QIV) strains</measure>
    <time_frame>Day 8 through Day 118</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects achieving neutralizing (Neut) titer seroconversion against 2018/2019 Quadrivalent Influenza Vaccine (QIV) antigens and strains</measure>
    <time_frame>Day 8 through Day 118</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects achieving neutralizing (Neut) titer seroconversion against 2019/2020 Quadrivalent Influenza Vaccine (QIV) strains</measure>
    <time_frame>Day 118</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects achieving neutralizing (Neut) titer seroconversion against heterologous H1 and H3 influenza strains</measure>
    <time_frame>Day 8 through Day 118</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects achieving seroconversion against heterologous N1 and N2 neuraminidase (NA) antigens</measure>
    <time_frame>Day 8 through Day 118</time_frame>
    <description>NA antigens will only be assessed on study groups 1, 2, and 3.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ratio of serum hemagglutination inhibition (HAI) geometric mean titer (GMT) against 2018/2019 Quadrivalent Influenza Vaccine (QIV) strains between adjuvanted and unadjuvanted study groups</measure>
    <time_frame>Day 8 through Day 118</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ratio of serum hemagglutination inhibition (HAI) geometric mean titer (GMT) against heterologous H1 and H3 influenza strains between adjuvanted and unadjuvanted study groups</measure>
    <time_frame>Day 1 through Day 118</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ratio of serum hemagglutination inhibition (HAI) geometric mean titers (GMTs) against 2019/2020 Quadrivalent Influenza Vaccine (QIV) strains between adjuvanted and unadjuvanted study groups</measure>
    <time_frame>Day 90 through Day 118</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ratio of serum neuraminidase inhibition (NAI) geometric mean titer (GMT) against 2018/2019 Quadrivalent Influenza Vaccine (QIV) strains between adjuvanted and unadjuvanted study groups</measure>
    <time_frame>Day 8 through Day 118</time_frame>
    <description>NAI titers will only be assessed on study groups 1, 2, and 3.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ratio of serum neuraminidase inhibition (NAI) geometric mean titers (GMTs) against 2019/2020 Quadrivalent Influenza Vaccine (QIV) strains between adjuvanted and unadjuvanted study groups</measure>
    <time_frame>Day 90 through Day 118</time_frame>
    <description>NAI titers will only be assessed on study groups 1, 2, and 3.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ratio of serum neuraminidase inhibition (NAI) geometric mean titers (GMTs) against heterologous N1 and N2 neuraminidase (NA) antigens between adjuvanted and unadjuvanted study groups</measure>
    <time_frame>Day 1 through Day 118</time_frame>
    <description>NAI titers will only be assessed on study groups 1, 2, and 3.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ratio of serum neutralizing (Neut) geometric mean titer (GMT) against 2018/2019 Quadrivalent Influenza Vaccine (QIV) strains between adjuvanted and unadjuvanted study groups</measure>
    <time_frame>Day 8 through Day 118</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ratio of serum neutralizing (Neut) geometric mean titers (GMTs) against 2019/2020 Quadrivalent Influenza Vaccine (QIV) strains between adjuvanted and unadjuvanted study groups</measure>
    <time_frame>Day 90 through Day 118</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ratio of serum neutralizing (Neut) geometric mean titers (GMTs) against heterologous H1 and H3 influenza strains between adjuvanted and unadjuvanted study groups</measure>
    <time_frame>Day 1 through Day 118</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum hemagglutination inhibition (HAI) geometric mean fold rise (GMFR) against 2019/2020 Quadrivalent Influenza Vaccine (QIV) strains</measure>
    <time_frame>Day 90 through Day 118</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum hemagglutination inhibition (HAI) geometric mean titer (GMT) against 2018/2019 Quadrivalent Influenza Vaccine (QIV) strains</measure>
    <time_frame>Day 8 through Day 118</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum hemagglutination inhibition (HAI) geometric mean titer (GMT) against heterologous H1 and H3 influenza strains</measure>
    <time_frame>Day 1 through Day 118</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum hemagglutination inhibition (HAI) geometric mean titers (GMTs) against 2019/2020 Quadrivalent Influenza Vaccine (QIV) strains</measure>
    <time_frame>Day 90 through Day 118</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum neuraminidase inhibition (NAI) geometric mean fold rise (GMFR) against 2019/2020 Quadrivalent Influenza Vaccine (QIV) strains</measure>
    <time_frame>Day 90 through Day 118</time_frame>
    <description>NAI titers will only be assessed on study groups 1, 2, and 3.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum neuraminidase inhibition (NAI) geometric mean titer (GMT) against 2018/2019 Quadrivalent Influenza Vaccine (QIV) strains</measure>
    <time_frame>Day 8 through Day 118</time_frame>
    <description>NAI titers will only be assessed on study groups 1, 2, and 3.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum neuraminidase inhibition (NAI) geometric mean titers (GMTs) against 2019/2020 Quadrivalent Influenza Vaccine (QIV) strains</measure>
    <time_frame>Day 90 through Day 118</time_frame>
    <description>NAI titers will only be assessed on study groups 1, 2, and 3.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum neuraminidase inhibition (NAI) geometric mean titers (GMTs) against heterologous N1 and N2 neuraminidase (NA) antigens</measure>
    <time_frame>Day 1 through Day 118</time_frame>
    <description>NAI titers will only be assessed on study groups 1, 2, and 3.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum neutralizing (Neut) geometric mean fold rise (GMFR) against 2019/2020 Quadrivalent Influenza Vaccine (QIV) strains</measure>
    <time_frame>Day 90 through Day 118</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum neutralizing (Neut) geometric mean titer (GMT) against 2018/2019 Quadrivalent Influenza Vaccine (QIV) strains</measure>
    <time_frame>Day 8 through Day 118</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum neutralizing (Neut) geometric mean titer (GMT) against heterologous H1 and H3 influenza strains</measure>
    <time_frame>Day 1 through 118</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum neutralizing (Neut) geometric mean titers (GMTs) against 2019/2020 Quadrivalent Influenza Vaccine (QIV) strains</measure>
    <time_frame>Day 90 through Day 118</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">241</enrollment>
  <condition>Influenza</condition>
  <condition>Influenza Immunisation</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.5 mL of 2018/2019 Fluzone QIV intramuscular injection on Day 1 and 0.5 ml of 2019/2020 Fluzone QIV intramuscular injection on Day 90, n=40</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.5 mL of 2018/2019 Fluzone QIV + 0.25 mL of AF03 (admixed with vaccine) intramuscular injection on Day 1 and 0.5 ml of 2019/2020 Fluzone QIV intramuscular injection on Day 90, n=40</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.5 mL of 2018/2019 Fluzone QIV + 0.5 mL of Delta Inulin-CpG55.2 (admixed with vaccine) intramuscular injection on Day 1 and 0.5 2019/2020 of Fluzone QIV intramuscular injection on Day 90, n=40</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.5 mL of 2018/2019 Flublok QIV intramuscular injection on Day 1 and 0.5 ml of 2019/2020 Flublok QIV intramuscular injection on Day 90, n=40</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.5 mL of 2018/2019 Flublok QIV + 0.25 mL AF03 (admixed with vaccine) intramuscular injection on Day 1 and 0.5 ml of 2019/2020 Flublok QIV intramuscular injection on Day 90, n=40</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.5 mL of 2018/2019 Flublok QIV + 0.5 mL of Delta Inulin-CpG55.2 (admixed with vaccine) intramuscular injection on Day 1 and 0.5 ml of 2019/2020 Flublok QIV intramuscular injection on Day 90, n=40</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AF03</intervention_name>
    <description>A squalene-in-PBS emulsion stabilized by nonionic surfactants, sorbitan oleate and macrogol cetostearyl ether</description>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_label>Group 5</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Delta Inulin-CpG55.2</intervention_name>
    <description>A combination adjuvant supplied as two separate components, Delta Inulin (Sypharma Pty Ltd.) and CpG55.2 (Nikko Denka Avecia and Sypharma Pty Ltd)</description>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_label>Group 6</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Influenza Virus Quadrivalent Inactivated Vaccine</intervention_name>
    <description>2018/2019 Fluzone QIV and 2019/2020 Fluzone QIV vaccines will be given with 90 days interval</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_label>Group 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Quadrivalent Recombinant Seasonal Influenza Vaccine</intervention_name>
    <description>2018/2019 Flublok QIV and 2019/2020 Flublok QIV vaccines will be given with 90 days interval</description>
    <arm_group_label>Group 4</arm_group_label>
    <arm_group_label>Group 5</arm_group_label>
    <arm_group_label>Group 6</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Provide written informed consent prior to initiation of any study procedures.&#xD;
&#xD;
          2. Are able to understand and comply with planned study procedures and be available for&#xD;
             all study visits.&#xD;
&#xD;
          3. Must agree to the collection of venous blood per protocol.&#xD;
&#xD;
          4. Are males or non-pregnant females, 18 to 45 years of age, inclusive at time of&#xD;
             enrollment.&#xD;
&#xD;
          5. Are in good health*. *As determined by medical history and physical examination to&#xD;
             evaluate acute or currently ongoing chronic medical or psychiatric diagnoses or&#xD;
             conditions, defined as those that have been present for at least 90 days, which would&#xD;
             affect the assessment of the safety of subjects or the immunogenicity of study&#xD;
             vaccinations. Chronic medical diagnoses or conditions should be stable for the last 60&#xD;
             days (no hospitalizations, emergency room or urgent care for condition, or invasive&#xD;
             medical procedure and no adverse symptoms that need medical intervention such as&#xD;
             medication change/supplemental oxygen). This includes no change in chronic&#xD;
             prescription medication, dose or in the 60 days prior to enrollment. Any prescription&#xD;
             change that is due to change of health care provider, insurance company, etc., or that&#xD;
             is done for financial reasons, as long as in the same class of medication, will not be&#xD;
             considered a deviation of this inclusion criterion. Subjects may be on chronic or as&#xD;
             needed (prn) medications if, in the opinion of the site PI or appropriate&#xD;
             sub-investigator, they pose no additional risk to subject safety or assessment of&#xD;
             reactogenicity and immunogenicity and do not indicate a worsening or treatment of&#xD;
             continued symptoms of medical diagnosis or condition. Note: Low dose topical,&#xD;
             corticosteroids as outlined in the Subject Exclusion Criteria as well as herbals,&#xD;
             vitamins and supplements are permitted.&#xD;
&#xD;
          6. Oral temperature is less than 100.0 degrees Fahrenheit.&#xD;
&#xD;
          7. Pulse is 47 to 100 beats per minute, inclusive.&#xD;
&#xD;
          8. Systolic blood pressure is 85 to 140 mmHg, inclusive.&#xD;
&#xD;
          9. Diastolic blood pressure is 55 to 90 mmHg, inclusive.&#xD;
&#xD;
         10. Screening laboratories (Erythrocyte Sedimentation Rate (ESR), White Blood Cells (WBC),&#xD;
             Hemoglobin (Hgb), Platelets (PLTs), Alanine Aminotransferase (ALT), Total Bilirubin&#xD;
             (T. Bili), Aspartate Aminotransferase (AST), Gamma-glutamyl Transferase (GGT),&#xD;
             Alkaline Phosphatase (ALP) serum lipase, serum amylase and Creatinine (Cr)) are within&#xD;
             acceptable parameters*.&#xD;
&#xD;
             *ESR must be below 30 mm/hr; WBC &gt;3.90 K/MM3 and &lt;10.60 K/MM3; Hgb &gt;/= 11.5 g/dl&#xD;
             (women) or &gt;/= 12.5 g/dl (men); PLTs (EDTA) 140-415 K/MM3; PLTs (Citrate) 125-325&#xD;
             K/MM3 ALT &lt;/= 43 U/L (women) or &lt;/= 60 U/L (men); T Bili &lt;/=1.20 mg/dl; Cr &lt; 1.1 mg/dl&#xD;
             (women) or &lt; 1.4 mg/dl (men); AST 10-36 U/L (women) or 10-43 U/L (men); GGT 5--32 U/L&#xD;
             (women) or 10-49 U/L (men); ALP 30-115 U/L (women) or 43-115 U/L (men); lipase 13-60&#xD;
             U/L; amylase (Total) 35-121 U/L, for subjects to qualify for randomization and&#xD;
             vaccination.&#xD;
&#xD;
         11. Women of childbearing potential* must use an acceptable contraception method** from at&#xD;
             least 30 days before the first study vaccination until 60 days after the second study&#xD;
             vaccination.&#xD;
&#xD;
             *Not sterilized via bilateral oophorectomy, tubal ligation/ salpingectomy,&#xD;
             hysterectomy, or successful Essure(R) placement (permanent, non-surgical, non-hormonal&#xD;
             sterilization) with documented radiological confirmation test at least 90 days after&#xD;
             the procedure, and still menstruating or &lt;1 year has passed since the last menses if&#xD;
             menopausal.&#xD;
&#xD;
               -  Includes non-male sexual relationships, full abstinence from sexual intercourse&#xD;
                  with a male partner, monogamous relationship with vasectomized partner who has&#xD;
                  been vasectomized for 180 days or more and shown to be azoospermic prior to the&#xD;
                  subject receiving the study vaccination, barrier methods such as condoms or&#xD;
                  diaphragms/cervical cap with spermicide, effective intrauterine devices,&#xD;
                  NuvaRing(R), and licensed hormonal methods such as implants, injectables or oral&#xD;
                  contraceptives (&quot;the pill&quot;).&#xD;
&#xD;
         12. Women of childbearing potential must have a negative urine or serum pregnancy test&#xD;
             within 24 hours prior to the first study vaccination.&#xD;
&#xD;
         13. For a woman with potential to become pregnant, she understands that in the event of&#xD;
             pregnancy during the study she will be approached to enroll in the Sanofi Pregnancy&#xD;
             Registry.&#xD;
&#xD;
         14. Must agree to have residual specimens (i.e. residual/excess of per protocol&#xD;
             specifications).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Have an acute illness*, as determined by the site Principal Investigator (PI) or&#xD;
             appropriate sub-investigator, within 72 hours prior to study vaccination.&#xD;
&#xD;
             *An acute illness which is nearly resolved with only minor residual symptoms remaining&#xD;
             is allowable if, in the opinion of the site PI or appropriate sub-investigator, the&#xD;
             residual symptoms will not interfere with the ability to assess safety parameters as&#xD;
             required by the protocol.&#xD;
&#xD;
          2. Have any medical disease or condition that, in the opinion of the site PI or&#xD;
             appropriate sub-investigator, is a contraindication to study participation*.&#xD;
&#xD;
             *Including acute, subacute, intermittent or chronic medical disease or condition that&#xD;
             would place the subject at an unacceptable risk of injury, render the subject unable&#xD;
             to meet the requirements of the protocol, or may interfere with the evaluation of&#xD;
             responses or the subject's successful completion of this trial.&#xD;
&#xD;
          3. Have immunosuppression as a result of an underlying illness or treatment, a recent&#xD;
             history or current use of immunosuppressive or immunomodulating disease therapy.&#xD;
&#xD;
          4. Use of anticancer chemotherapy or radiation therapy (cytotoxic) within 3 years prior&#xD;
             to study vaccination.&#xD;
&#xD;
          5. Have known active or recently active (12 months) neoplastic disease or a history of&#xD;
             any hematologic malignancy. Non-melanoma, treated, skin cancers are permitted.&#xD;
&#xD;
          6. Have known human immunodeficiency virus (HIV), hepatitis B or hepatitis C infection.&#xD;
&#xD;
          7. Have known hypersensitivity or allergy to eggs, egg or chicken protein, squalene-based&#xD;
             adjuvants, or other components of the study vaccine.&#xD;
&#xD;
          8. Have a history of severe reactions following previous immunization with licensed or&#xD;
             unlicensed influenza vaccines.&#xD;
&#xD;
          9. Have a history of Guillain-Barr√© Syndrome (GBS).&#xD;
&#xD;
         10. Have a history of convulsions or encephalomyelitis within 90 days prior to study&#xD;
             vaccination.&#xD;
&#xD;
         11. Have a history of Potentially Immune-Mediated Medical Conditions (PIMMCs).&#xD;
&#xD;
         12. Have a history of alcohol or drug abuse within 5 years prior to study vaccination.&#xD;
&#xD;
         13. Have any diagnosis, current or past, of schizophrenia, bipolar disease or other&#xD;
             psychiatric diagnosis that may interfere* with subject compliance or safety&#xD;
             evaluations.&#xD;
&#xD;
             *As determined by the site PI or appropriate sub-investigator.&#xD;
&#xD;
         14. Have been hospitalized for psychiatric illness, history of suicide attempt, or&#xD;
             confinement for danger to self or others within 5 years prior to study vaccination.&#xD;
&#xD;
         15. Have taken oral or parenteral (including intra-articular) corticosteroids of any dose&#xD;
             within 30 days prior to study vaccination.&#xD;
&#xD;
         16. Have taken high-dose inhaled corticosteroids* within 30 days prior to study&#xD;
             vaccination.&#xD;
&#xD;
             *High-dose defined as per age as using inhaled high-dose per reference chart in the&#xD;
             National Heart, Lung and Blood Institute Guidelines for the Diagnosis and Management&#xD;
             of Asthma (EPR-3) or other lists published in UPTODATE.&#xD;
&#xD;
         17. Received or plan to receive a licensed, live vaccine (excluding all licensed, seasonal&#xD;
             LAIVs) within 30 days before or after the study vaccination.&#xD;
&#xD;
         18. Received or plan to receive a licensed, inactivated vaccine (excluding all licensed,&#xD;
             seasonal IIVs) within 14 days before or after each study vaccination.&#xD;
&#xD;
         19. Have received any 2018/2019 seasonal influenza vaccine within the 6 months prior to&#xD;
             enrollment.&#xD;
&#xD;
         20. Plans to receive any 2019/2020 seasonal influenza vaccine within approximately 90 days&#xD;
             of receipt of the first study vaccination.&#xD;
&#xD;
         21. Have a known history of documented influenza infection within the past 6 months.&#xD;
&#xD;
         22. Received immunoglobulin or other blood products (except Rho D immunoglobulin) within&#xD;
             90 days prior to study vaccination.&#xD;
&#xD;
         23. Received an experimental agent* within 30 days prior to the study vaccination or&#xD;
             expect to receive another experimental agent* during the trial-reporting period*.&#xD;
&#xD;
             *Including vaccine, drug, biologic, device, blood product, or medication.&#xD;
&#xD;
             **Other than from participation in this trial.&#xD;
&#xD;
             ***Approximately 12 months after the first study vaccination.&#xD;
&#xD;
         24. Are participating or plan to participate in another clinical trial with an&#xD;
             interventional agent* that will be received during the trial-reporting period**.&#xD;
&#xD;
             *Including licensed or unlicensed vaccine, drug, biologic, device, blood product, or&#xD;
             medication.&#xD;
&#xD;
             **Approximately 12 months after the first study vaccination.&#xD;
&#xD;
         25. Female subjects who are breastfeeding or plan to breastfeed from the time of the first&#xD;
             study vaccination through 30 days after the last study vaccination.&#xD;
&#xD;
         26. Plan to travel outside the US (continental US, Hawaii and Alaska) from the time of&#xD;
             study vaccination through approximately 90 days after the first study vaccination.&#xD;
&#xD;
         27. Planning to donate blood within 4 months following first vaccination.&#xD;
&#xD;
        Exclusion Criteria for Second Study Vaccination:&#xD;
&#xD;
        All study participants will be expected to receive the second study vaccination except&#xD;
        under the circumstances listed below. The second study vaccination will not be administered&#xD;
        to a subject if any of the following criteria are met:&#xD;
&#xD;
          -  Meets the contraindication on the package insert to receipt of licensed influenza&#xD;
             vaccine.&#xD;
&#xD;
          -  As deemed necessary by the site principal investigator or appropriate sub-investigator&#xD;
             for noncompliance or other reasons.&#xD;
&#xD;
          -  Subject refusal of further study vaccination.&#xD;
&#xD;
          -  Withdrawal of consent.&#xD;
&#xD;
          -  Subject is lost to follow-up.&#xD;
&#xD;
          -  Termination of this trial.&#xD;
&#xD;
          -  New information becomes available that makes further participation unsafe.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Emory Children's Center - Pediatric Infectious Diseases</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322-1014</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Iowa - Vaccine Research and Education Unit</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242-2600</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Maryland Baltimore - School of Medicine - Medicine</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201-1509</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Louis University - Center for Vaccine Development</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63104-1015</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke Human Vaccine Institute - Duke Vaccine and Trials Unit</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27704</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital Medical Center - Infectious Diseases</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229-3039</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University - Pediatric - Vanderbilt Vaccine Research Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232-2573</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine - Molecular Virology and Microbiology</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030-3411</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 19, 2021</verification_date>
  <study_first_submitted>May 9, 2019</study_first_submitted>
  <study_first_submitted_qc>May 9, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 10, 2019</study_first_posted>
  <last_update_submitted>February 25, 2021</last_update_submitted>
  <last_update_submitted_qc>February 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Immunogenicity</keyword>
  <keyword>Influenza</keyword>
  <keyword>Influenza Vaccine</keyword>
  <keyword>Phase 1</keyword>
  <keyword>Quadrivalent</keyword>
  <keyword>Safety</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>June 4, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/25/NCT03945825/ICF_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <pending_results>
    <submitted>September 9, 2021</submitted>
    <returned>October 6, 2021</returned>
    <submitted>October 14, 2021</submitted>
    <returned>November 11, 2021</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

